Published in Cancer Causes Control on June 23, 2010
The role of vascular endothelial growth factor a polymorphisms in breast cancer. Int J Mol Sci (2012) 0.87
Association between the Functional Polymorphism of Vascular Endothelial Growth Factor Gene and Breast Cancer: A Meta-Analysis. Iran J Med Sci (2015) 0.79
The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients. BMC Genet (2015) 0.77
Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer. Cancer Biol Ther (2016) 0.75
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet (2006) 28.32
The biology of vascular endothelial growth factor. Endocr Rev (1997) 13.70
VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer (2002) 5.96
An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet (1997) 5.65
Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J (1999) 5.49
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development (1995) 4.05
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol (2009) 3.28
Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet (1999) 3.08
A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res (2001) 2.70
A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res (2003) 2.21
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol (2009) 1.97
A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer (2003) 1.88
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst (1997) 1.87
Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol (2002) 1.84
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res (2001) 1.70
Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol (2000) 1.68
Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer (2001) 1.67
Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res (2005) 1.66
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res (2005) 1.64
Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation (2000) 1.59
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer (1997) 1.40
Defects of DNA mismatch repair in human prostate cancer. Cancer Res (2001) 1.38
Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res (2006) 1.37
Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat (2001) 1.24
Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res (1995) 1.24
Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol (2004) 1.21
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res (1998) 1.18
Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol (2007) 1.17
Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res (2004) 1.17
IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun (2001) 1.16
Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res (1999) 1.15
p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer (2000) 1.14
Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev (2006) 1.11
The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res (2001) 1.10
TGF-betal/Smad signaling in prostate cancer. Curr Drug Targets (2003) 1.08
Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine (2006) 1.07
A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.04
Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control (2007) 1.02
Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer (2005) 1.00
Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res Treat (2005) 0.97
Association between genetic variations of vascular endothelial growth factor receptor 2 and atopy in the Korean population. J Allergy Clin Immunol (2006) 0.97
The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. Cancer Lett (2003) 0.95
Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs (2002) 0.92
Pathological significance of vascular endothelial growth factor A isoform expression in human cancer. Pathol Int (2002) 0.91
A common genetic factor underlies hypertension and other cardiovascular disorders. BMC Cardiovasc Disord (2004) 0.90
Role of vascular endothelial growth factor during breast cancer. Bull Exp Biol Med (2002) 0.87
Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. Clin Exp Metastasis (2007) 0.87
The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer. Biol Blood Marrow Transplant (2005) 0.83
Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF. Eur J Cancer (2010) 0.82
Large-scale population-based study shows no association between common polymorphisms of the TGFB1 gene and BMD in women. J Bone Miner Res (2007) 0.81
Novel agents and targets in managing patients with metastatic prostate cancer. Cancer Control (2006) 0.81
Antimestatic and antitumor activities of interleukin 10 in transfected human prostate PC-3 ML clones: Orthotopic growth in severe combined immunodeficient mice. Clin Cancer Res (1998) 0.80
IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. Invasion Metastasis (1997) 0.80
[The relationship between vascular endothelial growth factor, microvascular density, lymph node metastasis and prognosis of breast carcinoma]. Zhonghua Bing Li Xue Za Zhi (2000) 0.80
Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen. Br J Cancer (2003) 0.78
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
Laparoscopic liver resection: an examination of our first 300 patients. J Am Coll Surg (2011) 1.91
Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev (2010) 1.62
Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc Natl Acad Sci U S A (2003) 1.54
An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system. Arch Surg (2009) 1.42
Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med (2009) 1.40
Epidemiological trends of suicide and attempted suicide by poisoning in the US: 2000-2008. Leg Med (Tokyo) (2010) 1.15
Biological impact of missing-value imputation on downstream analyses of gene expression profiles. Bioinformatics (2010) 1.15
Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate (2010) 1.02
8q24 sequence variants in relation to prostate cancer risk among men of African descent: a case-control study. BMC Cancer (2010) 0.97
Potent inhibitors of LXXLL-based protein-protein interactions. Chembiochem (2005) 0.97
Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med (2013) 0.96
Interrogating differences in expression of targeted gene sets to predict breast cancer outcome. BMC Cancer (2013) 0.95
Interaction among apoptosis-associated sequence variants and joint effects on aggressive prostate cancer. BMC Med Genomics (2012) 0.94
Examination of polymorphic glutathione S-transferase (GST) genes, tobacco smoking and prostate cancer risk among men of African descent: a case-control study. BMC Cancer (2009) 0.93
Robust score statistics for QTL linkage analysis. Am J Hum Genet (2008) 0.90
Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med (2010) 0.89
S-adenosylmethionine decreases lipopolysaccharide-induced phosphodiesterase 4B2 and attenuates tumor necrosis factor expression via cAMP/protein kinase A pathway. J Pharmacol Exp Ther (2011) 0.89
Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response. Pharmacogenomics (2011) 0.88
To pump or not to pump: a comparison of machine perfusion vs cold storage for deceased donor kidney transplantation. J Am Coll Surg (2013) 0.85
Relationships of ESR1 and XBP1 expression in human breast carcinoma and stromal cells isolated by laser capture microdissection compared to intact breast cancer tissue. Endocrine (2011) 0.84
No association between variant N-acetyltransferase genes, cigarette smoking and Prostate Cancer susceptibility among men of African descent. Biomark Cancer (2011) 0.83
Retrospective review of intrauterine device in adolescent and young women. J Pediatr Adolesc Gynecol (2012) 0.83
A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen. Horm Cancer (2011) 0.82
Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study. Hered Cancer Clin Pract (2012) 0.81
Steroid receptor and growth factor receptor expression in human nonsmall cell lung cancers using cells procured by laser-capture microdissection. Adv Exp Med Biol (2008) 0.81
Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance. J Clin Lab Anal (2012) 0.81
Approaches to detecting gene x gene interaction in Genetic Analysis Workshop 14 pedigrees. Genet Epidemiol (2005) 0.81
Epigenetic analysis of laser capture microdissected fetal epithelia. Anal Biochem (2013) 0.80
MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma. Liver Transpl (2015) 0.79
Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status. Horm Cancer (2013) 0.79
Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses. Toxicol Sci (2012) 0.79
Developmental profiles of the murine palatal methylome. Birth Defects Res A Clin Mol Teratol (2013) 0.78
Associations between genetic variants in the TGF-β signaling pathway and breast cancer risk among Hispanic and non-Hispanic white women. Breast Cancer Res Treat (2013) 0.78
Machine perfusion: not just for marginal kidney donors. Am Surg (2015) 0.78
Co-expression of genes with estrogen receptor-α and progesterone receptor in human breast carcinoma tissue. Horm Mol Biol Clin Investig (2012) 0.77
Characterization of estrogen response element binding proteins as biomarkers of breast cancer behavior. Clin Biochem (2013) 0.77
Review of the use of hepatitis B core antibody-positive kidney donors. Transplant Rev (Orlando) (2010) 0.77
Risk of cancer in liver transplant recipients: a look into the mirror. Liver Transpl (2008) 0.77
Interaction between smoking history and gene expression levels impacts survival of breast cancer patients. Breast Cancer Res Treat (2015) 0.76
Molecular signatures of estrogen receptor-associated genes in breast cancer predict clinical outcome. Adv Exp Med Biol (2008) 0.76
Increasing utilization of human T-cell lymphotropic virus (+) donors in liver transplantation: is it safe? Transplantation (2009) 0.75
Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer. BMC Med Genomics (2014) 0.75
TGFβ-1 and Wnt-3a interact to induce unique gene expression profiles in murine embryonic palate mesenchymal cells. Reprod Toxicol (2010) 0.75
Is video laryngoscope-assisted flexible tracheoscope intubation feasible for patients with predicted difficult airway? A prospective, randomized clinical trial. Anesth Analg (2014) 0.75
Assessment of phytoestrogen and mycoestrogen recognition by recombinant human estrogen receptor-α using ligand titration arrays. Phytochem Anal (2013) 0.75
Temporal Expression of miRNAs in Laser Capture Microdissected Palate Medial Edge Epithelium from Tgfβ3(-/-) Mouse Fetuses. Microrna (2015) 0.75
Biosensors for detecting estrogen-like molecules and protein biomarkers. Adv Exp Med Biol (2008) 0.75
A three-tiered approach for calibration of a biosensor to detect estrogen mimics. Adv Exp Med Biol (2008) 0.75